Table 1 Patient characteristics

From: Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial

Characteristic

Number

Median age (range)

67.5 (20 – 87)

Sex—no. (%)

      Female

32 (48.5)

      Male

34 (51.5)

Pathologic diagnosis – no. (%)

      DLBCL, nGCB

47 (71.2)

      DLBCL, GCB

11 (16.7)

      DLBCL, NOS

3 (4.5)

      PCNSL

2 (3.0)

      PMBCL

2 (3.0)

      FL

1 (1.5)

IPI staging at diagnosis—no. (%)

      0–1

16 (24.2)

      2

13 (19.7)

      3

12 (18.2)

      4–5

23 (34.8)

     Not available (PCNSL patients)

2 (3.0)

Previous line of treatment—no. (%)

      1

32 (48.5)

      2

20 (30.3)

      3 or more§

14 (21.2)

Double expressor—no. (%)

      Yes

17 (25.8)

      No

29 (43.9)

      Not available

20 (30.3)

Double hit—no. (%)

      Yes

4 (6.1)‡

      No

31 (47.0)

      Not available

31 (47.0)

ECOG performance at the enrollment—no. (%)

      0

7 (10.6)

      1

53 (80.3)

      2 or more†

6 (9.1)

Baseline LDH—median (IQR)

333.5 (255.5, 534.8)

  1. Source data are provided as a Source Data file.
  2. §One patient had previously undergone five lines of treatment including one autologous stem cell transplantation. None of the patients had previously received more than four lines of treatment.
  3. †One patient had an ECOG performance status score of 3. The other patients had an ECOG performance status score of 2.
  4. ‡One patient had MYC, BCL2, and BCL6 translocation.
  5. DLBCL diffuse large B-cell lymphoma, ECOG European Cooperative Oncology Group, FL follicular lymphoma, IPI International Prognostic Index, IQR interquartile range, GCB germinal center B-cell type, LDH lactate dehydrogenase, nGCB non-germinal center B-cell type, NOS not otherwise specified, PCNSL primary central nervous system lymphoma, PMBCL primary mediastinal B-cell lymphoma.
Back to article page